Abstract Number: 369 • 2019 ACR/ARP Annual Meeting
Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases. Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…Abstract Number: 2469 • 2019 ACR/ARP Annual Meeting
Diversity of Poly-Functional T Cells in Psoriatic Arthritis and Rheumatoid Arthritis and Its Therapeutic Significance
Background/Purpose: Importance to specific T cell subpopulations has been attributed for specific diseases such as Th17 cells in psoriatic disease, Th1 cells in TB and…Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA). One…Abstract Number: 366 • 2018 ACR/ARHP Annual Meeting
Infectious Complications of Immunosuppressive Therapy in Patients with Common Variable Immunodeficiency (CVID) and Inflammatory Arthritis
Background/Purpose: Common variable immunodeficiency (CVID) is one of the most common symptomatic primary immunodeficiency syndrome with an incidence of ~1 in 25,000 people. CVID is…Abstract Number: 450 • 2018 ACR/ARHP Annual Meeting
Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
Background/Purpose: Injection Site Reaction (ISRs) are associated with the subcutaneous (SC) route of administration of all biologic agents, and 3% to 15% of patients reports…Abstract Number: 512 • 2018 ACR/ARHP Annual Meeting
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD)…Abstract Number: 605 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in patients (pts.) with active RA after treatment with at least one TNFi in a RCT. However,…Abstract Number: 1147 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany
Background/Purpose: Non-interventional studies (NIS) are essential instruments in pharmaceutical research not only for pharmaceutical companies but also for regulatory authorities or reimbursement bodies in Germany.…Abstract Number: 1386 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)
Background/Purpose: Golimumab has shown clinical efficacy and tolerability within its clinical trial program. No systematic outcome data regarding patient‐reported outcomes and health economic parameters reflecting…Abstract Number: 1392 • 2018 ACR/ARHP Annual Meeting
Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Background/Purpose: Injection site pain (ISP) is a component of the patient experience with injectable drugs. A new formulation of etanercept was developed to reduce ISP.…Abstract Number: 1660 • 2018 ACR/ARHP Annual Meeting
Depression Has a Greater Impact on Psoriatic Arthritis Than Rheumatoid Arthritis
Background/Purpose: Depression has been shown to be more common in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA), than in the general population. The…Abstract Number: 1983 • 2018 ACR/ARHP Annual Meeting
Mutations Associated with Clonal Hematopoiesis of Indeterminate Potential Are Found in Peripheral Blood and Synovial Fluid Macrophages from Patients with Rheumatoid and Psoriatic Arthritis
Background/Purpose: Myeloidmutations commonly associated to neoplasia in patients who do not meet the diagnostic criteria for myelodysplastic syndrome are coined as clonal hematopoiesis of indeterminate…Abstract Number: 2060 • 2018 ACR/ARHP Annual Meeting
Comparative Histologic and Molecular Analysis of Synovial Tissue in Early Treatment-Naïve Psoriatic and Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) are chronic joint conditions characterised by persistent inflammation of the synovial tissue (ST). Previous reports suggested less…Abstract Number: 1583 • 2017 ACR/ARHP Annual Meeting
Increase in Arginase Activity and Related Arginine Metabolites in Patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA): Potential Mechanisms for Endothelial Dysfunction
Background/Purpose: A high prevalence of CVD exists among patients with PsA and RA. The cardiovascular morbidity and mortality are hypothesized to be due in part…Abstract Number: 2524 • 2017 ACR/ARHP Annual Meeting
Weight Change before and after Diagnosis in Patients with Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis
Background/Purpose: Rheumatoid arthritis (RA) has been associated with weight loss around the time of diagnosis; little is known about weight change around diagnosis in…
- 1
- 2
- 3
- …
- 5
- Next Page »